ADXN Stock Overview
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.16 |
| 52 Week High | CHF0.26 |
| 52 Week Low | CHF0.036 |
| Beta | 1.76 |
| 1 Month Change | 83.33% |
| 3 Month Change | 200.94% |
| 1 Year Change | 38.70% |
| 3 Year Change | -90.21% |
| 5 Year Change | -90.78% |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
Mar 03
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
May 11Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)
Jun 10Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Mar 07What Type Of Returns Would Addex Therapeutics'(VTX:ADXN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 12Shareholder Returns
| ADXN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -18.2% | -5.2% | -1.8% |
| 1Y | 38.7% | 13.2% | -3.8% |
Return vs Industry: ADXN exceeded the Swiss Biotechs industry which returned 15.8% over the past year.
Return vs Market: ADXN exceeded the Swiss Market which returned -3.6% over the past year.
Price Volatility
| ADXN volatility | |
|---|---|
| ADXN Average Weekly Movement | 20.3% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: ADXN's share price has been volatile over the past 3 months.
Volatility Over Time: ADXN's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 24 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction.
Addex Therapeutics Ltd Fundamentals Summary
| ADXN fundamental statistics | |
|---|---|
| Market cap | CHF22.41m |
| Earnings (TTM) | -CHF10.56m |
| Revenue (TTM) | CHF1.65m |
13.6x
P/S Ratio-2.1x
P/E RatioIs ADXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXN income statement (TTM) | |
|---|---|
| Revenue | CHF1.65m |
| Cost of Revenue | CHF0 |
| Gross Profit | CHF1.65m |
| Other Expenses | CHF12.20m |
| Earnings | -CHF10.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 100.00% |
| Net Profit Margin | -640.91% |
| Debt/Equity Ratio | 0% |
How did ADXN perform over the long term?
See historical performance and comparison